Company Performance Metrics
Eun-Sang Moon: Chief Executive Officer- Sung-Kuon Chi: COO
SillaJen is a South Korean based biotechnology company headquartered in Busan South Korea, with satellite offices in Seoul South Korea and Financial District, San Francisco. The company is focused on the development and commercialization of oncolytic immunotherapy products using the SOLVE™ platform, including its lead product Pexa-Vec, which is
currently in Phase 3 trials for the treatment of advanced primary liver cancer.
2003. Jennerex, Inc. (San Francisco, USA) was established.
2014. SillaJen acquires Jennerex, Inc.
2015. In April 2015. SillaJen reached agreement with the US FDA on a Special Protocol Assessment (SPA) for multinational Phase 3 clinical trial of Pexa-Vec in Advanced Liver Cancer.
2015. In October 2015, SillaJen is selected as the major developer for the Government project of “Global State-of-the-art technology development for biomedical products."
2016. In January 2016, SillaJen announces first patient randomized in multinational Phase 3 trial for Pexa-Vec in Advanced Liver Cancer. In December 2016. SillaJen is listed on KOSDAQ market in South Korea.
2017. In may 2017, Sillajen signs collaborative agreement with Regeneron Pharmaceuticals for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.
In July 2017, SillaJen received approval from the China CFDA to commence phase 3 clinical trial for Pexa-Vec in liver cancer.
In Aug 2017, Sillajen signs collaborative agreement with the National Cancer Institute for development of combination therapy with Pexa-Vec and immune checkpoint inhibitors.
